Member Exclusive

Duchenne muscular dystrophy drug receives accelerated approval from FDA

The US Food and Drug Administration (Silver Spring, MD, USA) has granted accelerated approval for eteplirsen, making it the first drug treating the most common childhood form of muscular dystrophy to attain approval.

Go to the profile of Peter Brown
Sep 22, 2016

Please sign in or register for FREE

Register to MedChemNet

MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet.